Cogent Biosciences, Inc. Debt Securities, Available-for-sale, Amortized Cost
Cogent Biosciences, Inc. (COGT) had Debt Securities, Available-for-sale, Amortized Cost of $588.40 million as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-02-17
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $588.40M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $265.38M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $110.24M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $119.49M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-12-31 | $588.40M 10-K · filed 2026-02-17 |
| 2025-09-30 | $265.38M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $110.24M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $119.49M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $188.47M 10-K · filed 2026-02-17 |
| 2024-09-30 | $247.61M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $301.88M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $219.98M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $219.69M 10-K · filed 2025-02-25 |
| 2023-09-30 | $226.20M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $136.69M 10-Q · filed 2023-08-08 |
| 2022-12-31 | $119.49M 10-K · filed 2024-02-26 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-26 |
| 2018-12-31 | $22.93M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |